MASLD – Medxy AI

New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know

By MedXY 09/15/2026

An international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC burden in patients with MASLD.

Diabetes & Endocrinology Gastroenterology news

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD

By MedXY 08/30/2026

This prospective cohort study compares semaglutide, bariatric surgery, and lifestyle therapy in obese patients with MASLD, demonstrating semaglutide and surgery improve liver steatosis and fibrosis markers better than lifestyle changes alone, with semaglutide showing weight-independent benefits.

Diabetes & Endocrinology Gastroenterology news

Longitudinal Weight Changes in MASLD: Impact on Liver Outcomes and Disease Progression

By MedXY 08/19/2026

This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.

Gastroenterology news

Comparative Effectiveness of Shear Wave Elastography and VCTE in MASLD Risk Stratification: Insights from FIB-4-Based Two-Step Algorithms

By MedXY 08/15/2026

Shear wave elastography (SWE) shows comparable accuracy to vibration-controlled transient elastography (VCTE) for stratifying liver-related event risk in MASLD patients using FIB-4-based two-step algorithms.

Gastroenterology Nephrology news

Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD

By MedXY 08/14/2026

This article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages independently predict worse liver outcomes.

Diabetes & Endocrinology Gastroenterology news

Proteomic Insights into MASLD: Sex-Specific Endotypes and Predictive Value for Mortality

By MedXY 07/31/2026

A large-scale proteomic study identified distinct MASLD subtypes influenced by sex differences and developed a four-protein score predicting all-cause mortality, advancing personalized risk assessment beyond traditional liver-centric models.

Gastroenterology Internal Medicine news

Polypharmacy Challenges in Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: Navigating Care in a High-Risk Population

By MedXY 07/17/2026

Older adults with MASLD, especially those aged 75 and above, experience a high burden of polypharmacy linked to multimorbidity, necessitating careful medication management to balance disease control and geriatric vulnerabilities.

Gastroenterology Internal Medicine news

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study

By MedXY 07/16/2026

The G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD patients.

Gastroenterology news Pediatrics

Reclassifying Pediatric NAFLD: Insights from the Steatotic Liver Disease Framework in a Multicenter NASH CRN Study

By MedXY 07/15/2026

A multicenter study reclassifies pediatric NAFLD under the steatotic liver disease framework, revealing most children meet MASLD criteria, while highlighting alcohol and medication-related reclassifications that inform diagnosis and management.

Gastroenterology news Respiratory

Unraveling the KLF9-NR4A1-p38 MAPK Axis: A Novel Mechanism Linking Intermittent Hypoxia to MASLD in Obstructive Sleep Apnea

By MedXY 07/08/2026

This study elucidates how KLF9 mediates intermittent hypoxia-induced MASLD by suppressing NR4A1 and p38 MAPK signaling, paving the way for targeted therapies in OSA-associated metabolic liver disease.

Diabetes & Endocrinology Gastroenterology news

Global Insights into MASLD: Predictors of Fibrosis, Clinical Events, and Mortality from the Global-MASLD Study

By MedXY 07/03/2026

The Global-MASLD study identifies key predictors of advanced fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease, highlighting the prognostic value of noninvasive fibrosis markers across diverse populations.

Gastroenterology Internal Medicine news

Vibration-Controlled Transient Elastography vs. Liver Histology: Head-to-Head Prognostic Comparison in Metabolic Dysfunction-Associated Steatotic Liver Disease

By MedXY 07/01/2026

This study demonstrates that vibration-controlled transient elastography offers prognostic accuracy comparable to liver histology for predicting liver-related events in MASLD, supporting its role as a noninvasive alternative in clinical practice and trials.

Gastroenterology news Pathology & Lab Medicine/Bệnh học

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights

By MedXY 06/25/2026

This article explores a novel AI framework that identifies distinct collagen deposition patterns in MASLD, offering improved molecular specificity and prognostic value beyond traditional fibrosis assessments.

Gastroenterology Internal Medicine news

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds

By MedXY 06/17/2026

In adults with suspected MASH, 200 IU/day vitamin E lowered ALT as effectively as 400 IU/day and 800 IU/day over 24 weeks, with no short-term safety signal, supporting lower-dose use if vitamin E is chosen.

Diabetes & Endocrinology Gastroenterology news

Adolescent MASLD Plus PCOS Signals a Higher-Risk Cardiometabolic Trajectory Into Adulthood

By MedXY 05/28/2026

In the Raine Study, adolescents with both MASLD and PCOS had a substantially worse cardiometabolic profile by age 27 than peers with either condition alone, highlighting a high-risk subgroup that may warrant earlier metabolic surveillance.

Gastroenterology Internal Medicine news

HSP72-PRDX6 Control of PINK1 Ubiquitination Emerges as a New Mitophagy Axis in MASLD

By MedXY 05/01/2026

A new Hepatology study identifies an HSP72–PRDX6 pathway that restores PINK1/Parkin mitophagy, reduces hepatic steatosis, and worsens MASLD when disrupted in mice and hepatocytes.

Diabetes & Endocrinology Gastroenterology news

Oral Glucose Absorption Enhanced in Early Metabolic Dysfunction-Associated Steatotic Liver Disease

By MedXY 04/30/2026

New research reveals accelerated glucose absorption in early MASLD patients, independent of gastric emptying. This metabolic alteration may drive liver disease progression before hepatic insulin resistance develops.

Diabetes & Endocrinology Gastroenterology news

Early MASLD Is Associated With Enhanced Oral Glucose Absorption Independent of Gastric Emptying

By MedXY 04/30/2026

Stable-isotope OGTT data suggest that early MASLD is linked to higher oral glucose absorption, independent of gastric emptying, with preserved hepatic insulin suppression but impaired peripheral glucose clearance.

Diabetes & Endocrinology Gastroenterology news

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes

By MedXY 04/25/2026

A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.

Clinical Updates Gastroenterology news

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

By MedXY 04/02/2026

This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.